Martingale Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.4M	Buy	41,023 +39,347	+2,348%	+$5.22M	0.14%	160
2025 Q4	$238K	Buy	+1,676	New	+$243K	0.01%	728
2025 Q2	–	Sell	-3,196	Closed	-$353K	–	832
2025 Q1	$353K	Sell	3,196 -19,659	-86%	-$2.49M	0.01%	656
2024 Q4	$3.12M	Sell	22,855 -3,456	-13%	-$427K	0.08%	204
2024 Q3	$3.03M	Sell	26,311 -3,400	-11%	-$466K	0.07%	222
2024 Q2	$4.09M	Sell	29,711 -1,326	-4%	-$182K	0.09%	177
2024 Q1	$4.28M	Buy	31,037 +4,530	+17%	+$619K	0.09%	179
2023 Q4	$3.49M	Buy	26,507 +589	+2%	+$67.8K	0.07%	185
2023 Q3	$2.92M	Sell	25,918 -1,954	-7%	-$206K	0.06%	199
2023 Q2	$2.63M	Buy	27,872 +88	+0.3%	+$8.6K	0.05%	218
2023 Q1	$2.81M	Buy	27,784 +6,061	+28%	+$631K	0.05%	208
2022 Q4	$2.59M	Buy	+21,723	New	+$2.54M	0.05%	212